Cleary M P, Kasiske B, O'Donnell M P, Keane W F
Atherosclerosis. 1987 Jul;66(1-2):107-12. doi: 10.1016/0021-9150(87)90185-7.
The long-term effects of clofibric acid (200 mg/kg body weight) injected subcutaneously from 6-36 weeks of age were assessed in obese, hyperlipemic Zucker rats. At 18 and 36 weeks of age, treated rats had significantly lower fasted serum cholesterol levels but triacylglycerol levels were not affected. Rats were killed at 36 weeks of age at which time there were no differences in body and kidney weights between control and clofibric acid-treated rats. Liver, spleen and heart weights were lowered by clofibric acid treatment. In liver there was an elevation of lipid/g due to treatment but there were no effects on cholesterol/g or on either total liver lipid or cholesterol levels. In the epididymal fat pad of clofibric acid-treated rats, there was a 21% elevation of cholesterol level on a per pad basis. In the other organs, there were no effects of treatment on lipid or cholesterol levels except for lowered total cholesterol in kidney. Several liver lipogenic enzymes were lowered by treatment but malic enzyme was two times higher.
在肥胖、高脂血症的Zucker大鼠中评估了从6至36周龄皮下注射氯贝酸（200毫克/千克体重）的长期影响。在18周龄和36周龄时，接受治疗的大鼠空腹血清胆固醇水平显著降低，但三酰甘油水平未受影响。大鼠在36周龄时处死，此时对照大鼠和氯贝酸治疗的大鼠之间的体重和肾脏重量没有差异。氯贝酸治疗使肝脏、脾脏和心脏重量降低。在肝脏中，由于治疗脂质/克升高，但对胆固醇/克、肝脏总脂质或胆固醇水平均无影响。在氯贝酸治疗的大鼠附睾脂肪垫中，每个脂肪垫的胆固醇水平升高了21%。在其他器官中，除了肾脏中总胆固醇降低外，治疗对脂质或胆固醇水平没有影响。几种肝脏生脂酶因治疗而降低，但苹果酸酶升高了两倍。
